UST Earns Three CandE Awards for Candidate Experience Excellence in North America, EMEA, and APAC
Prestigious recognition includes number one overall rank for the EMEA region BENGALURU,…
Bioxodes positive Phase 2a stroke data show breakthrough potential of innovative therapeutic candidate BIOX-101
Safety endpoint met, with encouraging signs of efficacy in trial with 23…
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101
Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase…
